NervGen Pharma (NGEN) Stock Price, News & Analysis

Company Overview

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings. NervGen’s development activities center on progressing NVG-291 and related research through clinical trials to assess safety, tolerability and potential to improve functional outcomes for patients with neurological damage.

NervGen is publicly traded on the NASDAQ under the ticker NGEN and operates as a research-driven biopharmaceutical organization. The company conducts clinical development activities and research collaborations to support its programs and to advance regulatory development pathways for its therapeutics.

As a clinical-stage company, NervGen’s prospects are tied to the progress and results of its clinical trials and development partnerships. Its work is representative of the broader effort in biotechnology to develop novel regenerative treatments for conditions with significant unmet medical need in neurology. Investors and stakeholders typically follow clinical milestones and regulatory updates when evaluating the company’s progress.

Key Stats

• Today's Range: $3.74 to $3.93
• 50-Day Range: N/A
• 52-Week Range: $1.50 to $6.30
• Volume: 123,691 shs
• Average Volume: 166,637 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NGEN
• CIK: 1751912
• Web: N/A
• Phone: (604) 722-5361
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NervGen Pharma: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +380.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A